Prostate Cancer
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
December 8, 2023
Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity.
December 8, 2023
Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
December 7, 2023
Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer.
December 7, 2023
Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
December 7, 2023
Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation.
December 6, 2023
Long-Term Impact of Medicaid Expansion on Prostate Cancer Screening.
December 6, 2023
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.
December 6, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
December 6, 2023
Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration.
December 6, 2023
Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity.
December 5, 2023
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI.
December 5, 2023